IP Library › Granted Patent US 9,650,429
Granted Patent B2
US 9,650,429 · App. 14/617,090 · Granted May 16, 2017

Soluble CD80 as a therapeutic to reverse immune suppression in cancer patients

Inventor: Suzanne Ostrand-Rosenberg (Columbia, MD)
Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
C07K14/70532C07K2317/76C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,650,429
App. No.
14/617,090
Granted
May 16, 2017
Kind
B2
Abstract

The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.

Claims (2)

1. A binding complex comprising a chimeric peptide bound to PDL1 on a tumor cell, wherein the chimeric peptide comprises a soluble CD80 amino acid sequence and a Fc IgG1 amino acid sequence, wherein the soluble CD80 amino acid sequence consists of SEQ ID NO: 4, wherein the soluble CD80 bound to PDL1 on the tumor cell inhibits or reduces binding of PD1 to PDL1.

2. The binding complex of claim 1 , wherein the Fc IgG1 amino acid sequence comprises SEQ ID NO: 8.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2024
From: OSTRAND-ROSENBERG, SUZANNE
To: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
Reel/Frame 067393/0725 →
Continuity (3)
Division 13660037 · Oct 25, 2012
Provisional Application 61551113 · Oct 25, 2011
Related Publication 20150232532A1 · Aug 20, 2015